EUCTR2014-005634-59-DK进行中（未招募）1 期
Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH) - TEACH
Aarhus University Hospital0 个研究点目标入组 16 人开始时间: 2015年4月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Documented HIV-1 infection
- •Age >18 years
- •CD4+ T-cell count >350/µL at screening
- •On cART (for a minimum of 12 months)
- •Able to give informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy as determined by a positive urine beta-hCG (if female)
- •Males or females who are unwilling or unable to use barrier contraception during sexual intercourse for the entire study period.
- •Currently breast-feeding (if female)
- •Viral load (HIV RNA) > 50 copies/mL
- •Contraindication to receive MGN1703 as per current investigator brochure
- •Presence of acute bacterial infection or undiagnosed febrile condition
- •Concurrent chronic systemic immune therapy or immunosuppressant medication, including continuous systemic steroid treatment within the last 2 weeks prior to randomization
- •Use of antibiotic therapy within the last 2 weeks prior to randomization
- •Known HBV or HCV infection
- •Any medical, psychiatric, social, or occupational condition or other responsibility that, in the judgment of the Principal Investigator (PI), would interfere with the evaluation of study objectives (such as severe alcohol abuse, severe drug abuse, dementia)
- •Unable to follow protocol regimen
研究者
相似试验
已完成
1 期
Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected AdultsHIV InfectionsNCT00562939University of Aarhus97
已完成
1 期
Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 InfectionHIVNCT02443935University of Aarhus12
进行中（未招募）
1 期
Combining a TLR9 agonist with broadly neutralizing antibodies forreservoir reduction and immunological control of HIV infection: Aninvestigator-initiated randomized, placebo-controlled, phase IIa trial(TITAN)EUCTR2018-001165-16-NODepartment of infectious Diseases, Aarhus University Hospital48
进行中（未招募）
1 期
Combining a TLR9 agonist with broadly neutralizing antibodies for reservoir reduction and immunological control of HIV infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial (TITAN)HIV infectionMedDRA version: 20.1Level: LLTClassification code 10073675Term: HIV infection CDC category unspecifiedSystem Organ Class: 100000004862EUCTR2018-001165-16-DKDepartment of infectious Diseases, Aarhus University Hospital48
招募中
1 期
Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT ( VS-TC )Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapiesMedDRA version: 20.1Level: PTClassification code 10056559Term: Graft infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-005150-28-ITIRCCS ISTITUTO GIANNINA GASLINI10